KA/EN
Register
Medicines reference
Search
Search
Active substance

Thiamine

Favourites

B vitamin. Registered in Georgia: 1 veterinary product and 2 human medicines. Forms: coated tablet, emulsion, solution.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

Known Contraindications

  • Warning
    Sodium metabisulfite (E223) can rarely cause severe hypersensitivity reactions and bronchospasm. The tablet also contains the azo dyes Ponceau 4R (E124) and Sunset Yellow (E110). Riboflavin can turn urine yellow; this is expected and is not an adverse effect.
    Sources: Product label
Latin name
Thiamine
Georgian name
თიამინი
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
3 of 3 forms
Products
Benevron B, Benevron BF, VITATOX
Human medicines in Georgia
Vitamin B1 Sopharma
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration3

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Benevron B, Solution

solution for injection, 3 ml ampoule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed deep-IM use of the exact Benevron B human ampoule for a diagnosed vitamin deficiency or adjunctive neurologic role
Not rateable
No numerical score assigned
vetman assessment

Benevron B

solution for injection, 3 ml ampoule, human medicine
Assessed clinical scopeDog · Proposed deep-IM use of the exact Benevron B human ampoule for a diagnosed vitamin deficiency or adjunctive neurologic role · Intramuscular
Care settingVeterinarian-directed use only after diagnosis and selection of a source-backed, deliverable regimen
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, human · № რ-045603, რ-038060 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical canine score cannot be assigned responsibly. AEM DV 22-01101 and Kazakhstan SPC ҚР-ДЗ-5№121984 verify the exact 3 ml human ampoule, four-vitamin composition and deep-IM human route. They provide no dog/cat dose, veterinary PK, target-animal safety margin or clinical outcome evidence. The human schedule and an isolated clinic-chart volume are not transferable, and the ampoule also contains 60 mg benzyl alcohol.

Exact human identity and deep-IM route are verified; a veterinary dose and benefit-risk are not. Do not transfer the human schedule or infer “slow injection.”

Important safety and use flags

  • Use only for a defined deficiency or other explicit clinical rationale. A nonspecific neurologic sign, anorexia, fatigue or routine supplementation is not a diagnosis.
  • No dog or cat dose is established for this exact ampoule. Do not scale the human schedule, copy an isolated clinic-chart volume or derive a mixture dose from one component.
  • The exact official route is deep IM. “Slowly” is not stated in the audited primary documents; do not add it or extrapolate IV, SC or oral use.
  • AEM and the Kazakhstan SPC describe a human medicine; this is not a veterinary authorisation. Exact dog/cat PK, efficacy and repeated-dose safety remain absent.
  • Do not infer that all B vitamins are required because one deficiency is plausible. Ingredient or comparator evidence cannot validate this fixed high-dose ratio or transfer another product’s dose.
  • Each 3 ml ampoule contains 250 mg pyridoxine and 60 mg benzyl alcohol with the other vitamins. Dog/cat local tolerance, repeated-dose safety and therapeutic margin are not established.
  • High experimental pyridoxine exposure caused sensory-neuron injury in dogs. Those studies do not define a safe lower Benevron regimen, but they rule out assuming that water solubility makes chronic high-dose exposure harmless.
  • Parenteral thiamine can cause serious hypersensitivity. Use aseptic technique, review excipients and ensure readiness to manage an acute reaction.
  • Review the full medication plan, especially levodopa without a peripheral decarboxylase inhibitor and other vitamin-containing products. Avoid unexamined cumulative exposure.
  • Set a diagnosis-specific response point and stop date. If response is absent, reassess diet, malabsorption, antagonists, primary disease and the actual deficient nutrient rather than continuing empirical B-complex treatment.
Assessment sources
  1. Benevron B Azerbaijan register2022
  2. Benevron B Kazakhstan SPC2026
  3. Small-animal nutrition2026
  4. Feline thiamine case2010
  5. Veterinary B12 comparator2025
  6. Canine oral pyridoxine toxicity1981
  7. Canine parenteral pyridoxine toxicity2008
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed deep-IM use of the exact Benevron B human ampoule for a diagnosed vitamin deficiency or adjunctive neurologic role
Not rateable
No numerical score assigned
vetman assessment

Benevron B

solution for injection, 3 ml ampoule, human medicine
Assessed clinical scopeCat · Proposed deep-IM use of the exact Benevron B human ampoule for a diagnosed vitamin deficiency or adjunctive neurologic role · Intramuscular
Care settingVeterinarian-directed use only after diagnosis and selection of a source-backed, deliverable regimen
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, human · № რ-045603, რ-038060 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical feline score cannot be assigned responsibly. AEM DV 22-01101 and Kazakhstan SPC ҚР-ДЗ-5№121984 verify the exact 3 ml human ampoule, four-vitamin composition and deep-IM human route. They provide no dog/cat dose, veterinary PK, target-animal safety margin or clinical outcome evidence. The human schedule and an isolated clinic-chart volume are not transferable, and the ampoule also contains 60 mg benzyl alcohol.

Exact human identity and deep-IM route are verified; a veterinary dose and benefit-risk are not. Do not transfer the human schedule or infer “slow injection.”

Important safety and use flags

  • Use only for a defined deficiency or other explicit clinical rationale. A nonspecific neurologic sign, anorexia, fatigue or routine supplementation is not a diagnosis.
  • No dog or cat dose is established for this exact ampoule. Do not scale the human schedule, copy an isolated clinic-chart volume or derive a mixture dose from one component.
  • The exact official route is deep IM. “Slowly” is not stated in the audited primary documents; do not add it or extrapolate IV, SC or oral use.
  • AEM and the Kazakhstan SPC describe a human medicine; this is not a veterinary authorisation. Exact dog/cat PK, efficacy and repeated-dose safety remain absent.
  • Do not infer that all B vitamins are required because one deficiency is plausible. Ingredient or comparator evidence cannot validate this fixed high-dose ratio or transfer another product’s dose.
  • Each 3 ml ampoule contains 250 mg pyridoxine and 60 mg benzyl alcohol with the other vitamins. Dog/cat local tolerance, repeated-dose safety and therapeutic margin are not established.
  • High experimental pyridoxine exposure caused sensory-neuron injury in dogs. Those studies do not define a safe lower Benevron regimen, but they rule out assuming that water solubility makes chronic high-dose exposure harmless.
  • Parenteral thiamine can cause serious hypersensitivity. Use aseptic technique, review excipients and ensure readiness to manage an acute reaction.
  • Review the full medication plan, especially levodopa without a peripheral decarboxylase inhibitor and other vitamin-containing products. Avoid unexamined cumulative exposure.
  • Set a diagnosis-specific response point and stop date. If response is absent, reassess diet, malabsorption, antagonists, primary disease and the actual deficient nutrient rather than continuing empirical B-complex treatment.
Assessment sources
  1. Benevron B Azerbaijan register2022
  2. Benevron B Kazakhstan SPC2026
  3. Small-animal nutrition2026
  4. Feline thiamine case2010
  5. Veterinary B12 comparator2025
  6. Canine oral pyridoxine toxicity1981
  7. Canine parenteral pyridoxine toxicity2008
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Thiamine83.33 mg/ml Pyridoxine83.33 mg/ml Cyanocobalamin0.5 mg/ml Riboflavin1.333 mg/ml
Formulation Type
Solution
Administration route
Intramuscular
Registration
Georgia Yes, human
In force until 02 Jun 2031
Human (Ministry of Health, RAMA)
№ რ-045603, რ-038060
Verified on: 15 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog or cat dose was identified for this exact high-dose four-vitamin ampoule. The official human information specifies deep intramuscular administration; it does not say slowly and its human schedule cannot establish a veterinary ml/kg regimen.

Benevron BF 20 gastro-resistant tablets, Coated tablet

human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role
Not rateable
No numerical score assigned
vetman assessment

Benevron BF

20 gastro-resistant tablets, human medicine
Assessed clinical scopeDog · Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role · By mouth
Care settingVeterinarian-directed use only after diagnosis and selection of a source-backed, deliverable regimen
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, human · № რ-046262, რ-044386 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical canine score cannot be assigned responsibly. AEM DV 25-00460 verifies the Azerbaijani gastro-resistant medicine, while the exact World Medicine Kazakhstan document describes the same name, composition and 20-tablet presentation as a food supplement. Neither source establishes a dog/cat regimen, veterinary PK, target-animal safety or outcomes; neither establishes a validated veterinary fraction.

Exact identity is documented, but the regulatory category differs by jurisdiction and no veterinary dose or validated tablet fraction is established.

Important safety and use flags

  • Use only for a defined deficiency or other explicit clinical rationale. A nonspecific neurologic sign, anorexia, fatigue or routine supplementation is not a diagnosis.
  • No dog or cat dose is established for this exact product. Do not restore a quarter-tablet practice or derive a fraction by arithmetic.
  • The exact presentation is gastro-resistant, but the audited primary documents do not establish scoring, equal-dose subdivision, whole-only administration or crushing instructions. Do not invent any of them.
  • AEM records a human medicine in Azerbaijan; the exact World Medicine Kazakhstan document calls the same name/composition/presentation a food supplement. Keep the jurisdiction-specific categories distinct.
  • Do not infer that all B vitamins are required because one deficiency is plausible. Ingredient or comparator evidence cannot validate this fixed high-dose ratio or transfer another product’s dose.
  • Each tablet contains 200 mg pyridoxine with four other vitamins. No product-specific dog/cat exposure threshold, safe duration or therapeutic margin is established.
  • High experimental pyridoxine exposure caused sensory-neuron injury in dogs. Those studies do not define a safe lower Benevron regimen, but they rule out assuming that water solubility makes chronic high-dose exposure harmless.
  • Review hypersensitivity to active ingredients and excipients. The exact product document lists sulfite and paraben excipients; target-animal tolerability is not established.
  • Review the full medication plan, especially levodopa without a peripheral decarboxylase inhibitor and other vitamin-containing products. Avoid unexamined cumulative exposure.
  • Set a diagnosis-specific response point and stop date. If response is absent, reassess diet, malabsorption, antagonists, primary disease and the actual deficient nutrient rather than continuing empirical B-complex treatment.
Assessment sources
  1. Benevron BF Azerbaijan register2025
  2. Benevron BF manufacturer document2026
  3. Small-animal nutrition2026
  4. Feline thiamine case2010
  5. Veterinary B12 comparator2025
  6. Canine oral pyridoxine toxicity1981
  7. Canine parenteral pyridoxine toxicity2008
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role
Not rateable
No numerical score assigned
vetman assessment

Benevron BF

20 gastro-resistant tablets, human medicine
Assessed clinical scopeCat · Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role · By mouth
Care settingVeterinarian-directed use only after diagnosis and selection of a source-backed, deliverable regimen
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, human · № რ-046262, რ-044386 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical feline score cannot be assigned responsibly. AEM DV 25-00460 verifies the Azerbaijani gastro-resistant medicine, while the exact World Medicine Kazakhstan document describes the same name, composition and 20-tablet presentation as a food supplement. Neither source establishes a dog/cat regimen, veterinary PK, target-animal safety or outcomes; neither establishes a validated veterinary fraction.

Exact identity is documented, but the regulatory category differs by jurisdiction and no veterinary dose or validated tablet fraction is established.

Important safety and use flags

  • Use only for a defined deficiency or other explicit clinical rationale. A nonspecific neurologic sign, anorexia, fatigue or routine supplementation is not a diagnosis.
  • No dog or cat dose is established for this exact product. Do not restore a quarter-tablet practice or derive a fraction by arithmetic.
  • The exact presentation is gastro-resistant, but the audited primary documents do not establish scoring, equal-dose subdivision, whole-only administration or crushing instructions. Do not invent any of them.
  • AEM records a human medicine in Azerbaijan; the exact World Medicine Kazakhstan document calls the same name/composition/presentation a food supplement. Keep the jurisdiction-specific categories distinct.
  • Do not infer that all B vitamins are required because one deficiency is plausible. Ingredient or comparator evidence cannot validate this fixed high-dose ratio or transfer another product’s dose.
  • Each tablet contains 200 mg pyridoxine with four other vitamins. No product-specific dog/cat exposure threshold, safe duration or therapeutic margin is established.
  • High experimental pyridoxine exposure caused sensory-neuron injury in dogs. Those studies do not define a safe lower Benevron regimen, but they rule out assuming that water solubility makes chronic high-dose exposure harmless.
  • Review hypersensitivity to active ingredients and excipients. The exact product document lists sulfite and paraben excipients; target-animal tolerability is not established.
  • Review the full medication plan, especially levodopa without a peripheral decarboxylase inhibitor and other vitamin-containing products. Avoid unexamined cumulative exposure.
  • Set a diagnosis-specific response point and stop date. If response is absent, reassess diet, malabsorption, antagonists, primary disease and the actual deficient nutrient rather than continuing empirical B-complex treatment.
Assessment sources
  1. Benevron BF Azerbaijan register2025
  2. Benevron BF manufacturer document2026
  3. Small-animal nutrition2026
  4. Feline thiamine case2010
  5. Veterinary B12 comparator2025
  6. Canine oral pyridoxine toxicity1981
  7. Canine parenteral pyridoxine toxicity2008
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Thiamine250 mg Pyridoxine200 mg Riboflavin15 mg Folic acid0.5 mg Cyanocobalamin0.25 mg
Formulation Type
Coated tablet
Administration route
By mouth
Registration
Georgia Yes, human
In force until 08 Sep 2031
Human (Ministry of Health, RAMA)
№ რ-046262, რ-044386
Verified on: 15 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog or cat dose was identified for this exact high-dose five-vitamin gastro-resistant product. The exact public documents contain human directions only and do not establish tablet subdivision, crushing, veterinary exposure or a treatment course.

VITATOX 50 ml emulsion for injection for dogs and cats, Emulsion

vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full dog label: parenteral supportive therapy with glucose, sorbitol and vitamins A, D3, B1, nicotinamide and C at a fixed 10-15 ml per animal
4.9/10
Weak evidence support
vetman assessment

VITATOX

50 ml emulsion for injection for dogs and cats
Assessed clinical scopeDog · Full dog label: parenteral supportive therapy with glucose, sorbitol and vitamins A, D3, B1, nicotinamide and C at a fixed 10-15 ml per animal · SC,IM,IV,IP
Care settingClinic supportive care, given slowly IV or by another labelled route, alongside diagnosis and specific treatment
vetman score 4.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 61-11 · Verified on 22 Oct 2026

A weak option: an authorised but old-style sugar and vitamin emulsion with little evidence of benefit and a fixed dose that ignores body size. Give targeted fluids, dextrose or a specific vitamin only when a need is shown.

Regulatory and scientific credibility5.5/10

The dog and cat product holds an Italian national authorisation listed in the EU database (UPD 600000097476), a real regulator record, but it is an older authorisation with no published efficacy data; Georgia lists it as 61-11 with no validity date.

Clinical efficacy3.5/10

Glucose gives short-lived energy and vitamins help only a true deficiency; no controlled study shows clinical benefit for the labelled supportive uses, and current fluid guidelines use measured fluids and dextrose instead.

Safety and tolerability5.5/10

The dose is fixed at 10-15 ml regardless of size, giving 20,000-30,000 IU of vitamin D3 and 500-750 mg of glucose per dose; the label excludes hyperglycaemia and the first third of pregnancy and warns of vitamin excess.

Clinical practicality5.5/10

Slow IV injection in clinic is straightforward, but the emulsion must not be mixed with other drugs and an opened vial lasts 28 days.

Full-course cost-effectiveness-

No verified current Georgian price or patient-adjusted course cost was found; foreign prices were not substituted.

Important safety and use flags

  • Do not use with hyperglycaemia, including diabetes, or hypersensitivity to an ingredient; avoid in the first third of pregnancy because vitamin A can be teratogenic.
  • Each dose contains 20,000-30,000 IU of vitamin D3; do not repeat routinely, and check calcium if doses are repeated.
  • Inject IV slowly; do not mix with other medicines because compatibility has not been studied.
  • The dose is per animal, not per kg; use the lower 10 ml dose for small dogs.
  • Use within 28 days of opening; protect from light and heat.
Assessment sources
  1. EU UPD VITATOX2025
  2. Georgia NFA register 20262026
  3. AAHA fluid therapy 20242024
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full cat label: parenteral supportive therapy with glucose, sorbitol and vitamins A, D3, B1, nicotinamide and C at a fixed 10-15 ml per animal
4.6/10
Weak evidence support
vetman assessment

VITATOX

50 ml emulsion for injection for dogs and cats
Assessed clinical scopeCat · Full cat label: parenteral supportive therapy with glucose, sorbitol and vitamins A, D3, B1, nicotinamide and C at a fixed 10-15 ml per animal · SC,IM,IV,IP
Care settingClinic supportive care, given slowly IV or by another labelled route, alongside diagnosis and specific treatment
vetman score 4.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 61-11 · Verified on 22 Oct 2026

A weak option for cats: an old-style sugar and vitamin emulsion with little evidence of benefit and a dog-sized fixed dose that delivers a high vitamin D load to a small cat. Use measured fluids, dextrose or a specific vitamin when a need is shown.

Regulatory and scientific credibility5.5/10

The dog and cat product holds an Italian national authorisation listed in the EU database (UPD 600000097476), a real regulator record, but it is an older authorisation with no published efficacy data; Georgia lists it as 61-11 with no validity date.

Clinical efficacy3.5/10

Glucose gives short-lived energy and vitamins help only a true deficiency; no controlled study shows clinical benefit for the labelled supportive uses, and current fluid guidelines use measured fluids and dextrose instead.

Safety and tolerability4.5/10

The same fixed 10-15 ml dose as for dogs gives a 3-4 kg cat roughly 5,000-10,000 IU/kg of vitamin D3 and a large glucose load in one injection; the label excludes hyperglycaemia and the first third of pregnancy and warns of vitamin excess.

Clinical practicality5.0/10

10-15 ml is a large single volume for a cat by any route, the IV injection must be slow, and the emulsion must not be mixed with other drugs.

Full-course cost-effectiveness-

No verified current Georgian price or patient-adjusted course cost was found; foreign prices were not substituted.

Important safety and use flags

  • Do not use with hyperglycaemia, including diabetes, or hypersensitivity to an ingredient; avoid in the first third of pregnancy because vitamin A can be teratogenic.
  • Each dose contains 20,000-30,000 IU of vitamin D3, a high load for a cat; use the lower 10 ml dose, do not repeat routinely, and check calcium if repeated.
  • Check blood glucose in sick or stressed cats before giving 500-750 mg of glucose plus sorbitol.
  • Inject IV slowly; do not mix with other medicines because compatibility has not been studied.
  • Use within 28 days of opening; protect from light and heat.
Assessment sources
  1. EU UPD VITATOX2025
  2. Georgia NFA register 20262026
  3. AAHA fluid therapy 20242024
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Glucose50 mg/ml Sorbitol50 mg/ml Nicotinamide1.2 mg/ml Ascorbic Acid8 mg/ml Thiamine0.36 mg/ml Cholecalciferol2000 IU/ml Vitamin A400 IU/ml
Formulation Type
Emulsion
Administration route
Subcutaneous, Intramuscular, Intravenous, IP
Manufacturer
Fatro S.p.A. · Italy
Manufacturer (register)
Fatro S.P.A., Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1334, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ვიტატოქსი
№ 61-11
Verified on: 22 Oct 2026
Controlled in Georgia
Unknown

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 22 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗